Key points from article :
Having announced a $100m Longevity Co-Investment Fund (LCIF) last year, Maximon is now trying to attract pre-clinical researchers with a Longevity Prize for Translational Research worth around £40K (US$54K).
The prize will be awarded to anyone who has published breakthrough research or holds the patent on science that could be translated into clinical or non-clinical applications.
This means academics, non-profit researchers, students and startup founders can apply if they have demonstrated a proof of concept in pre-clinical lab studies.
As well as the prize, it looks like Maximon will provide a lot of practical support too.
What is great about Maximon is they are very open about their intentions - they're looking for advanced research that has the potential to substantially increase health span or life span of humans. With many in the industry shying away from the radical impact some rejuvenation interventions, I'm glad they are happy to state the objective clearly.
01-Mar-2022 : open for applications
31-Jul-2022 : application window closed
31-Aug-2022 : evaluation phase complete
29-Sep-2022: award ceremony
Maximon has convened an impressive jury to judge the applications:
- Dr. Ashish Rajput, CSO at Maximon
- Prof. Brian Kennedy, National University of Singapore
- Prof. Dr. Collin Y. Ewald, ETH Zurich
- Sebastien Thuault, Chief Editor of Nature Aging
- Prof. Dr. Evelyne Yehudit Bischof, MD, MPH - Shanghai University of Medicine & Health Sciences